

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(37 CFR 1.98(b))

ATTY. DOCKET NO.

97-092-US

SER. NO.

08/833,842

APPLICANT

KAESEMEYER

FILING DATE

April 10, 1997

GROUP ART UNIT

1614

U.S. PATENT DOCUMENTS

Examiner Initial	Patent Number	Issue Date	Patentee	Class/Subclass	Filing Date
DK	5,543,430	Aug. 6, 1996	Kaesemeyer	514/565	
DK	5,428,070	Jun. 27, 1995	Cooke et al.	514/557	
DK	5,316,765	May 31, 1994	Folkers et al.	424/94.1	
DK	5,196,195	Mar. 23, 1993	Griffith	424/94.6	
DK	5,158,883	Oct. 27, 1992	Griffith	435/240.2	
DK	5,132,453	Jul. 21, 1992	Griffith	562/560	
DK	5,059,712	Oct. 22, 1991	Griffith	562/560	
DK	4,686,211	Aug. 11, 1987	Hara et al.	514/142	

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
AA		Patel, J. M. et al. <u>Nitric Oxide Exposure and Sulfhydryl Modulation Alter L-Arginine Transport in Cultured Pulmonary Artery Endothelial Cells.</u> (Abstract Only) Free Radical Biology & Medicine. Vol. 20, No. 5. pp. 629. 1996.
AB		Xia, Y. et al. <u>Nitric Oxide Synthase Generates Superoxide and Nitric Oxide in Arginine-Depleted Cells Leading to Peroxynitrite-Mediated Cellular Injury.</u> Proc. Natl. Acad. Sci. USA. Vol. 93. pp. 6770-6774. June 1996.
AC		Jeremy, R. W. et al. <u>Effects of Dietary L-Arginine on Atherosclerosis and Endothelium-Dependent Vasodilation in the Hypercholesterolemic Rabbit.</u> Circulation. Vol. 94, No. 3. pp. 498-506. August 1, 1996.
AD		Block, E. R. et al. <u>Hypoxia Inhibits L-Arginine Uptake By Pulmonary Artery Endothelial Cells.</u> (Abstract Only) Am. J. Physiol. Vol. 269. L574-L580. 1995.
AE		Mayer, B. et al. <u>Brain Nitric Oxide Synthase is a Biopterin-and Flavin-Containing Multi-Functional Orido-Reductase.</u> (Abstract Only) FEBS 10045. Vol. 288, No. 1,2. pp. 187-191. August 1991.
AF		Weidinger, F. F. et al. <u>Persistent Dysfunction of Regenerated Endothelium After Balloon Angioplasty of Rabbit Iliac Artery.</u> Circulation. Vol. 81, No. 5. pp. 1667-1679. May 1990.

DATE CONSIDERED

August 3, 1997

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SER. NO.

97-092-US

08/833,842

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

KAESEMEYER

FILING DATE

April 10, 1997

GROUP ART UNIT

1614

(37 CFR 1.98(b))

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	
	BA Chester, A. H. et al. <u>Low Basal and Stimulated Release of Nitric Oxide in Atherosclerotic Epicardial Coronary Arteries</u> . The Lancet. Vol. 336. pp. 897-900. Oct. 13, 1990.
	BB Albina, J. E. et al. <u>Arginine Metabolism in Wounds</u> . Am. J. Physiol. Vol. 254. pp. E459-E467. 1988.
	BC Cooke, J.P. et al. <u>Antiatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit</u> . (Abstract Only) J. Clin. Invest. Vol. 90, No. 3. pp. 1168-72. Sep. 1992.
	BD Nakamura, Y. et al. <u>Pravastatin Reduces Restenosis After Coronary Angioplasty of High Grade Stenotic Lesions: Results of SHIPS (SHIga Pravastatin Study)</u> . (Abstract Only). Cardiovasc. Drugs. Ther., Vol. 10, No. 4, pp. 475-483. 1996.
	BE Pohl, U. et al. <u>Effects of LDL on Intracellular Free Calcium and Nitric Oxide-Dependent cGMP Formation on Porcine Endothelial Cells</u> . (Abstract only) Atherosclerosis. Vol. 117. pp. 169-178. 1995.
	BF Deliconstantinos, G. et al. <u>Modulation of Particulate Nitric Oxide Synthase Activity and Peroxynitrate Synthesis in Cholesterol Enriched Endothelial Cell Membranes</u> . (Abstract Only) Biochem. Pharm. Vol. 49. No. 11. pp. 1589-1600. 1995.
	BG Galle, J. et al. <u>Effect of HDL and Atherogenic Lipoproteins on Formation of O₂ and Renin Release in Juxtaglomerular Cells</u> . (Abstract Only) Kidney International. Vol. 51. pp. 253-260. 1997.
	BH Bult, H. <u>Nitric Oxide and Atherosclerosis: Possible Implications for Therapy</u> . (Abstract only) Molecular Medicine Today. p. 510. December 1996.
	BI Crouse III, J.R. et al. <u>Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)</u> . (Abstract only) Am. J. Cardiol. Vol. 75. pp. 455-459. 1995.
	BJ Aji, W. et al. <u>L-Arginine Prevents Xanthoma Development and Inhibits Atherosclerosis in LDL Receptor Knockout Mice</u> . (Abstract only) Circulation. Vol. 95. pp. 430-437. 1997.
	BK Cooke, J. P. et al. <u>Arginine: A new Therapy for Atherosclerosis?</u> Circulation. Vol. 95. pp. 311-12. 1997.
	BL Boger, R. H. et al. <u>The L-Arginine Nitric Oxide Pathway: Role in Atherosclerosis and Therapeutic Implications</u> . (First page only) Atherosclerosis. Vol. 127. pp. 1-11. 1996.
	DATE CONSIDERED <i>August 3, 1997</i>

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

97-092-US

SER. NO.

08/833,842

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

KAESEMEYER

FILING DATE

April 10, 1997

GROUP ART UNIT

1614

(37 CFR 1.98(b))

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
	CA	Jay, M.T. et al. <u>Modulation of Vascular Tone By Low Density Lipoproteins. Effects on L-Arginine Transport and Nitric Oxide Synthesis.</u> Experimental Physiology. Vol. 82. pp. 349-360. 1997.
	CB	Muramatsu, J. et al. <u>Hemodynamic Changes Associated with Reduction in Total Cholesterol By Treatment with the HMG-CoA Reductase Inhibitor Pravastatin.</u> Atherosclerosis. Vol. 130. pp. 179-182. 1997.
	CC	Sacks, F. M. et al. <u>The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels.</u> The New England Journal of Medicine. Vol. 335. pp. 1001-1009. October 3, 1996.
	CD	Bovan, A. J. van. et al. <u>Reduction of Transient Myocardial Ischemia with Pravastatin in Addition to the Conventional Treatment in Patients with Angina Pectoris.</u> Circulation. Vol. 94. pp. 1503-1505. 1996.
	CE	Lacoste, L. et al. <u>Comparative Effect of Pravastatin and Simvastatin on Platelet-Thrombus Formation in Hypercholesterolemic Coronary Patients.</u> JACC. Vol. 27 No. 2 Supp A. p. 413A. 1996.
	CF	Pitt, B. et al. <u>Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in Atherosclerosis Progression and Clinical Events.</u> J. Am. Coll. Cardiol. Vol. 26. pp. 1133-9. 1995.
	CG	Candipan, R.C. et al. <u>Regression or Progression: Dependency on Vascular Nitric Oxide.</u> Arterioscler. Thromb. Vas. Biol. Vol. 16. pp. 44-50. 1996.
	CH	Byington, R.P. et al. <u>Reduction in Cardiovascular Events During Pravastatin Therapy. Pooled Analysis of Clinical Events of the Pravastatin Atherosclerosis Intervention Program.</u> Circulation. Vol. 92. pp. 2419-2425. 1995.
	CI	Pritchard, K.A. et al. <u>Native Low-Density Lipoprotein Increases Endothelial Cell Nitric Oxide Synthase Generation of Superoxide Anion.</u> Circ. Res. Vol. 77 No. 3. pp. 510-518. 1995.
	CJ	Boger, R.H. et al. <u>Supplementation of Hypercholesterolemic Rabbits with L-Arginine Reduces the Vascular Release of Superoxide Anions and Restores NO Production.</u> Artherosclerosis. Vol. 117 No. 2. pp. 273-284. 1995.

DATE CONSIDERED

August 3, 1998

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SER. NO.

97-092-US

08/833,842

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

KAESEMEYER

FILING DATE

April 10, 1997

GROUP ART UNIT

1614

(37 CFR 1.98(b))

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
	DA	Lacoste, L. et al. <u>Correction of the Increased Thrombogenic Potential with Cholesterol Reduction</u> . Circulation. Vol 92. pp. 3172-3177. 1995.
	DB	Shepard, J. <u>Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia</u> . The New England Journal of Medicine Vol. 333. pp. 1301-1307. November 16, 1995.
	DC	Philis-Tsimikas, A. et al. <u>L-Arginine May Inhibit Atherosclerosis Through Inhibition of LDL Oxidation</u> . Circulation. Vol. 92 (Supp. I). pp. I-422. 1995.
	DD	Von der Leyen, H.E. et al. <u>Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene</u> . Proc. Natl. Acad. Sci. USA. Vol. 92. pp. 1137-1141. 1995.
	DE	Egashira, K. et al. <u>Reduction in Serum Cholesterol with Pravastatin Improves Endothelium-Dependent Coronary Vasomotion in Patients with Hypercholesterolemia</u> . Circulation. Vol. 89. pp. 2519-2524. 1994.
	DF	Tsao, P. et al. <u>Enhanced Endothelial Adhesiveness in Hypercholesterolemia is Attenuated by L-Arginine</u> . Circulation. Vol. 89. pp. 2176-2182. 1994.
	DG	Cayatte, A.J. et al. <u>Chronic Inhibition of Nitric Oxide Production Accelerates Neointima Formation and Impairs Endothelial Function in Hypercholesterolemic Rabbits</u> . Arterioscler. Thomb. Vol. 14. pp. 753-759. 1994.
	DH	Wilcox, J.N. et al. <u>Expression of Multiple Nitric Oxide Synthase Isoforms in Human Aortic Fatty Streaks and Advanced Atherosclerotic Plaques</u> . (Abstract only) Circulation. Vol. 90 (Supp. I). pp. I-298. 1994.
	DI	Chen, L. Y. et al. <u>Oxidized LDL Decreases L-Arginine Uptake and Nitric Oxide Synthase Protein Expression in Human Platelets: Relevance of the Effect of Oxidized LDL on Platelet Function</u> . Circulation. Vol. 93. pp. 1740-1746. 1993.
	DJ	Wada, H. et al. <u>Hypercoagulable State in Patients with Hypercholesterolemia: Effects of Pravastatin</u> . Clin. Therap. Vol. 14. pp. 829-34. 1992.
	DK	Dresler, H. et al. <u>Correction of Endotelial Dysfunction in Coronary Microcirculation of Hypercholesterolaemia Patients by L-Arginine</u> . The Lancet. Vol. 338. pp. 1546-1550. Dec. 21/28, 1991.

DATE *August 3, 1997*
CONSIDERED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SER. NO.

97-092-US

08/833,842

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT

KAESEMEYER

FILING DATE

April 10, 1997

GROUP ART UNIT

1614

(37 CFR 1.98(b))

OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial		
	EA	Haman, M. et al. <u>Long-Term Oral Administration of L-Arginine Reduces Intimal Thickening and Enhances Neoendothelium-Dependent Acetylcholine-Induced Relaxation After Arterial Injury.</u> Circulation, Vol. 90. No. 3, pp. 1357-1362. September, 1994.
	EB	Harrison, D.G. <u>Endothelial Modulation of Vascular Tone: Relevance to Coronary Angioplasty and Restenosis.</u> J. Am. Coll. Cardiol. Vol. 17. pp. 71B-6B. 1991.
	EC	Cooke, J.P. et al. <u>Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta.</u> Circulation, Vol. 83. pp. 1057-1062. 1991.
	ED	Witzum, J.L. et al. <u>Role of Oxidized Low Density Lipoprotein in Atherogenesis.</u> J. Clin. Invest. Vol. 88. pp. 1785-1792. 1991.
	EE	Mugge, A.J. et al. <u>Chronic Treatment with Polyethylene-Glycolated Superoxide Dismutase Partially Restores Endothelium-Dependent Vascular Relaxations in Cholesterol-Fed Rabbits.</u> Circ. Res. Vol. 69. pp. 1293-1300. 1991.
	EF	Forstermann, U. et al. <u>Selective Attenuation of Endothelium-Mediated Vasodilation in Atherosclerotic Human Coronary Arteries.</u> Circ. Res. Vol. 62. pp. 185-191. 1988.
	EG	Cohen, R.A. et al. <u>Loss of Selective Endothelial Cell Vasoactive Functions in Pig Coronary Arteries During Hypercholesterolemia.</u> Circ. Res. Vol. 63. pp. 903-910. 1988.
	EH	Schwarzacher, A.P. et al. <u>Locak Intramural Delivery of L-Arginine Enhances Nitric Oxide Generation and Inhibit Lesion Formation After Balloon Angioplasty.</u> Circulation, Vol. 95. No. 7. pp. 1863-1869. April 1, 1997.
	EI	Verbeuren, T.J. et al. <u>Effect of Hypercholesterolemia on Vascular Reactivity in the Rabbit. I: Endothelium-Dependent and Independent Contractions and Relaxations in Isolated Arteries of Control and Hypercholesterolemic Rabbits.</u> Circ. Res. Vol. 58. pp. 552-564. 1986.

DATE
CONSIDERED

August 3, 1997

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
 (MODIFIED) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT

(37 CFR 1.98(b))

ATTY. DOCKET NO.

97-092-US

SER. NO.

08/833,842

APPLICANT

KAESEMEYER

FILING DATE

April 10, 1997

GROUP ART UNIT

1614

OTHER DOCUMENTS
 (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial			
	FA	Duggan, D.E. et al. <u>The Physiological Disposition of Lovastatin</u> . Drug Metabolism and Disposition, Vol. 17, No. 2. pp. 166-173. 1989.	
	FB	Vickers, S. et al. <u>Metabolic Disposition Studies on Simvastatin, a Cholesterol-Lowering Prodrug</u> . Drug Metabolism and Disposition, Vol. 18, No. 2. pp. 138-145. 1990.	
			DATE CONSIDERED
			